Status and phase
Conditions
Treatments
About
Study in two stages, and with a sub-study.
Full description
Stage A: To determine efficacy of lenalidomide as single agent in patients with recurrent ovarian cancer in second or third line.
Stage B: To determine the Maximum Tolerated Dose (MTD) of lenalidomide in combination with chemotherapy consisting of carboplatin and pegylated liposomal doxorubicin.
Substudy: To investigate the impact of the lenalidomide on patients' immune system affected by cancer and to look for an immunizing marker which could be predictive of the activity of the lenalidomide in the solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Stage A: Patient:
Stage B: Patients
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
67 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal